The cyanobacteria and predominantly the genus Nostoc are known as producers of dozens pharmacologically active compounds, composed of abnormal amino acids, which have aided them to survive in varied and highly competitive ecological niches. Their function as antiviral, antitumour, antibacterial, anti-HIV and a food additive has been well set up. This high degree of chemical diversity in bioactive compounds of cyanobacterial Nostoc species may thus create a prolific source of new entities leading to the development of new pharmaceuticals. This review provides the comprehensive overview of metabolites and novel bioactive natural products produced by cyanobacteria of the genus Nostoc, which present biological activity and can be used for the treatment of various human and animal disorders.
Introduction
The medicinal and nutrient qualities of cyanobacteria were first realized as early as 1500 BC, when Nostoc species were used to treat gout, fistula and several forms of cancer. [1] Nostoc species are a rich source of bioactive compound. [2] They are belonging to the family Nostocaceae, which contains different bioactive components like phenolics, phycocyanin, triterpenoids amino acids, poly-unsaturated fatty acids, sulphates polysaccharides and carotenoids. [3] These components are specific for antimicrobial, antioxidant and antibacterial activity. Many of these compounds are strong toxins and constitute a health risk for humans and animals either by disrupting the normal functioning of the liver (hepatotoxin) or by nerve cells (neurotoxins). [2, 4, 5] Microcystins and nodularins are hepatotoxic cyclic peptides that are strong inhibitors of eukaryotic protein phosphatase type 1 and 2A. The ability to tolerate a great range of environmental conditions has made Nostoc species very competitive. [6] As a result, Nostoc species are found in a wide variety of habitats both free living and as symbionts. Nostoc species can be found in fresh, brackish and marine waters, in a wide range of terrestrial environments, and in addition, they also occupy a variety of environmental extremes such as hot springs and glaciers. [6] [7] [8] Nostoc blooms in eutrophic waters produce strong toxins and bioactive compounds thereby causing health problem both for humans and for animals. [2] What are the bioactive natural products?
Natural products are an integral source of new pharmaceuticals and pharmaceutical 'lead' compounds. Natural products supply not only as drugs in their own right, but they may also supply as structural models for the creation of synthetic analogues. Of the 974 compact molecules, recent chemical entities lunched as drugs worldwide during 1981-2006, 63% were influenced by natural products. [9, 10] These encompass natural products (6%), natural product derivatives (28%), artificial compounds with natural product-derived pharmacophores (5%), and the others are artificial compounds based on knowledge benefited from a natural product. In specific therapeutic areas, the productivity was higher: 77.8% of anticancer drugs are either natural products or derived from natural products. The enormous majority of active compounds have been derived from fungi, bacteria and plants ( Figure 1) . [11] A vital problem in focusing on these sources in the search for new, biologically active molecules is the rediscovery of previously known natural products. One way to minimize this problem is to develop selective bioassays and explore new therapeutic areas. Another approach is to look at new and different sources of natural products. Natural products have been derived from a wide variety of taxa and tested for various biological activities. Among these taxa, Nostoc cyanobacteria species demonstrate such a source. They have been identified as a new and rich source of bioactive compounds. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Multiple bioactive compounds derived from different Nostoc strains demonstrated novel and a varied range of biological activities and chemical structures including novel peptides (e.g. cyclic depsipeptides, cyclic peptides, lipopeptides), fatty acids, polyketides, alkaloids, amides, terpenes, carbohydrates and other organic chemicals. [12, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Many of these are regarded as good candidates for drug discovery, with applications in agriculture, [35] industry [18, 25, 36] and, especially, in pharmacy. [17, 21, 22, 24, [36] [37] [38] The bioactive compounds of Nostoc species supply novel and useful pharmaceuticals that are hard to produce artificially because of their structural complexity. [39] They are proved to have an engrossing and exciting range of biological activities ranging from antimicrobial, anticancer, antiviral, immunosuppressant, insecticidal, anti-inflammatory to proteinase-inhibiting activities which are notable targets of biomedical research (Table 1) . [28, 37, 38, [40] [41] [42] [43] [44] Nonribosomal peptide biosynthesis A wide range of bacterial and fungal bioactive compounds are synthesized by immense multifunctional enzymes called nonribosomal peptide synthetases (NRPSs). These metabolites include antibiotics (e.g. gramicidin S, tyrocidine and surfactin), siderophores (e.g. mycobactin and enterobactin), toxins (e.g. syringomycin microcystins and HC toxin) and immunosuppressive agents (e.g. rapamycin and cyclosporine). The presence of unusual and nonproteinogenic amino acids with modifications in the peptide backbone suggests that many Nostoc peptides are synthesized nonribosomal by the peptide synthetases. [45] Modular peptide synthetases Nonribosomal peptide synthetases have a modular structure and catalyse peptide formation by the thiotemplate mechanism. [45] A complete minimum module in peptide synthetases is responsible for the activation, thioesterification and condensation of one specific amino acid substrate. The adenylation domain recognizes a substrate, which can be either an amino acid or a hydroxyl acid and activates it as aminoacyl adenylate at the expense of adenosine triphosphate (ATP). The adenylation domains of the peptide synthetases belong to a large superfamily of adenylate-forming enzymes that includes luciferases and acyl CoA synthases. Binding of the substrate takes place at the thiolation domain where amino acyl substrate is covalently linked to the enzyme bound 4 phosphopantetheine (4 PP) cofactor. This reaction yields the amino acyl thioester, and adenosine monophosphate (AMP) is released. Thiolation domains resemble the acyl carrier proteins (ACPs) found in fatty acid and polyketide synthases and are therefore called peptidyl carrier proteins. The two amino or hydroxyl acids that are activated on adjacent modules are then joined together. Formation of the peptide bond and elongation of the growing peptide chain is mediated by the condensation domain. Peptide synthetases modules may also contain additional modifying domains. Modifications of the amino acids, such as epimerization and N-methylation, are catalysed by additional domains. Epimerization domain catalyses the L to D transformation of the amino acid, while N-methylation is mediated by a methylation domain. Chlorination of the amino acid is thought to be arbitrated by the halogenase domain. Terminal thioesterase domains catalyse the release of the peptide product by hydrolysis (linear peptides) or by cyclization (cyclic peptides). In many NRPSs, the organization and the order of the modules correspond to the amino acid sequence of the peptide product. This is known as the colinearity rule which means that the chemical structure of a peptide can be inferred from the order of the individual genes within the nonribosomal gene cluster. However, some exception to this colinearity rule has been found. [46] A crystallization study of the adenylation domain of gramicidin S was the basis for the determination of the substrate Figure 1 The percentage of chemical entities derived from the natural product. specificity of the NRPS adenylation domains. Comparison of the amino acid sequence of the gramicidin S synthase A (GrsA) phenylalanine activating (PheA) domain with the sequences of over 150 other adenylation domains has led to the design of an amino acid specificity code. [46] This code allows the prediction of amino acid substrate specificity of NRPS adenylation domains from gene sequence data. Peptide synthetases contain particular substrate binding pockets where the amino acids specifying the substrate are located. Also, condensation domains are now believed to play a role in amino acid substrate specificity. [47] Modular polyketide synthases Several cyanobacteria peptides carry polyketide or fatty acid side chains. Like the nonribosomally synthesized peptides, polyketides are generated by large multifunctional protein complexes that are organized into modules. [45] Polyketide synthesis resembles the synthesis of fatty acids. A typical module in a modular polyketide synthase (PKS) is responsible for one discrete chain elongation step. [48] The ketosynthase domain (KS domain) catalyses the condensation between polyketide acyl chain and (methyl)-malonyl-COA acyl carrier protein (ACP). (methyl)-malonyl-COA is formed in another reaction catalysed by acyltransferase domain (AT domain). Additional PKS domains are needed for the modifications of the growing polyketide chain. [49] High-value metabolites from cyanobacteria Anticancer and cytotoxicity compounds Nostopeptin BN920, Nostoginin BN741, Nostoginin BN578, Banyascyclamide A, Banyascyclamide B and Banyascyclamide C Six new metabolites, viz. Nostopeptin BN920, Nostoginin BN741, Nostoginin BN578, Banyascyclamide A, Banyascyclamide B and Banyascyclamide C, were derived from the hydrophilic extract of a Nostoc sp. [48] For purification of these compounds, first they naturally collected, freeze-dried cells were extracted with MeOH: H 2 O and then with MeOH: chloroform. The different fractions were separated on Sephadex column and then were subjected to a reversephase HPLC. Nostopeptin BN920 interdicts the serine endopeptidase chymotrypsin, while Nostoginin BN741 interdicts a bovine aminopeptidases (EC 3.4.11). [48] The inhibitory activity of Nostopeptin BN920 was determined against two enzymes, the serine endopeptidases trypsin and chymotrypsin. Moreover, this compound inhibits chymotrypsin with IC 50 0.11 lmol/l, but not trypsin at 45.0 g/ml. Nostoginin BN741 interdicts a bovine aminopeptidase with IC 90 1.3 lmol/l, but does not inhibit bovine neutral endopeptidase and peptidyl-dipeptidase A at 48 lg/ml. [50] Unfortunately, there also is no record of animals testing.
Boron-containing macrocycles (Borophycin)
Borophycin is the strong cytotoxic in the lipophilic extract of a marine strain of the cyanobacterium N. linckia and from Nostoc spongiaeforme var. [48] Tenue. Four new cyclic hexapeptides containing no boron, tenuecyclamides A-D, were also derived from the methanol extract of Nostoc spongiaeforme var. Tenue. Borophycin exhibits strong cytotoxicity against human epidermoid carcinoma and human colorectal adenocarcinoma cell lines and has been found to exhibit antimicrobial activity. [12] Nostocyclin Nostocyclin, a novel 3-amino-6-hydroxy-2-piperidone-containing cyclic peptide, was derived from a hepatotoxic strain of cyanobacterium Nostoc sp. Isolating of this compound was in stationary phase. The methanolic freeze-died biomass was suspended in acetic acid, and further purification was done by reverse-phase HPLC. The yield of the inhibitor was 35 mg. Nostocyclin is nontoxic in acute in vivo bioassays but interdicts phosphoprotein phosphatase activity at high concentration IC 50 of 64 lmol/l (1280 9 higher than microcystin-LR) in vitro. [22] This compound was not toxic in an intrapersonal mouse bioassay or in a brine shrimp bioassay.
Cryptophycin
Cryptophycin 1 first derived from Nostoc sp. ATCC 53789 is a strong fungicide. It was also found to be very toxic. Next, it was also derived from Nostoc sp. GSV 224 and has showed strong cytotoxicity against human tumour cell lines. The mechanism of cytotoxicity of the cryptophycins is tubulin interaction, with a disruption of tubulin dynamics, resulting in apoptosis of tumour cells. It shows good activity against a broad spectrum of drug-sensitive and drug-resistant murine and human solid tumours. Unfortunately, almost all of the studies have used only in vitro assays; it is likely that most of secondary compounds will have little or no application in medicine as they are either too toxic or are inactive in vivo. However, they serve as useful leads to create new synthetic bioactive compounds. For example, Cryptophycin-8 was a semisynthetic analogous which proved to have a greater therapeutic efficiency and lower toxicity that cryptophycin 1 in vivo. [48] Consequently, Cryptophycin 52, a synthetic analogue, was developed and used for clinical trials. It was chosen because no large-scale biotechnological production method existed for the cryptophycins. However, the high-production costs and toxic side effects of cryptophycin 52 stopped its development. To date, investigations are going to find in a very comprehensive way the biosynthetic of the cryptophycins, which may make this drug more easily accessible and less costly to produce. [12] Nostosins Two recent trypsin inhibitors, nostosin A and B, were derived from a hydrophilic extract of Nostoc sp. strain FSN, which was gathered from a paddy field in the Golestan Province of Iran. Nostosin A is the first highly strong threesubunit trypsin inhibitor with potency comparable to the studied commercial trypsin inhibitor leupeptin. [51, 52] 
Antiviral compound
There has been growing interest in the development of antiviral microbicides, which are defined as agents that may be used ex vivo or topically to inhibit the spread of viral infection. Here, we introduced antiviral compounds that have been isolated recently from Nostoc species.
Indolo
Then, fractions were separated further by successive normal and reversed-phase chromatography. These compounds are responsible for most of the cytotoxicity and antiviral activity related with the blue-green alga N. sphaericum EX-5-1. These compounds are active against HSVII and show weak cytotoxicity against KB and LoVo human carcinoma cell lines and moderate antiviral activity against herpes simplex virus type 2. For example, in infected mink lung cells, the virus titre is reduced 95%. [48] Cyanovirin-N Cyanovirin-N (CV-N) is a matchless, 101 amino acid long, 11-kDa protein. It was discovered as a component of a cultured cyanobacterium, Nostoc ellipsosporum, and both the sequence and the 3-D structure of CV-N are unprecedented. Anti-HIV screening of the extract and fractions thereof and the initial testing of pure proteins were performed by the XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt) assay. Isolation of the active protein was accomplished by high-performance liquid chromatography (HPLC) on a lBondapak C 18 matrix column which was eluted with a water acetonitrile gradient. CV-N strongly and irreversibly inactivates various primary strains of HIV-1, in nanomolar concentrations. It interferes with the binding of HIV gp120 proteins with CD4þ receptors and the chemokine CCR5 or CXCR4 coreceptors of target cells, and, thus, interdicts fusion of HIV virus with CD4 cell membrane. It also interdicts herpes simplex virus-6 and measles virus in vitro. [22] Nostoflan Nostoflan, an acidic polysaccharide from Nostoc flagelliforme that shows strong viricidal activity against herpes simplex virus-1, is also noteworthy. Moreover, this compound showed strong antiviral activity against HSV-2, human cytomegalovirus and influenza A virus. However, there was no activity against adenovirus and coxsackie virus. [22, 48] Therefore, Nostoflan has a broad antiviral spectrum against enveloped viruses whose cellular receptors are carbohydrates. Furthermore, Nostoflan showed no antithrombin activity, unlike sulphated polysaccharides, and there also is no record of animals testing. Extraction and isolation of this antiviral polysaccharide were done by anion-exchange chromatography, and fractions were extracted by Sepharose 6B column and Toyopearl HW55F column. [48] 
Antibacterial compounds Comnostins
Five new extracellular metabolites with an unprecedented diterpenoid skeleton, named as comnostin A, B, C, D and E, have been derived from N. commune. All comnostins A-E represented antibacterial activity. Also, cytotoxic and molluscicidal activities were found for comnostin B. [48, 53, 54] Muscoride A A new oligopeptide alkaloid, muscoride A, was derived from terrestrial freshwater N. muscorum. Muscoride A was the first composite possessing N-(2-methylbut-3-en-2-yl) valine and two contiguous methyloxazoles. Muscoride A showed feeble antibacterial activity against Bacillus subtilis and Escherichia coli.
[48]
Noscomin
The diterpenoid composite, Noscomin, has been derived from the culture medium of the terrestrial N. commune. [48] Noscomin represented antibacterial activity against Bacillus cereus, Staphylococcus epidermidis and Escherichia coli. These merits are comparable with those captured for the standards chloramphenicol and tetracycline. [48, [55] [56] [57] 
Carbamidocyclophanes
Carbamidocyclophanes are paracyclophanes derived from Nostoc sp. CAVN 10. They show middling antibacterial activity against Staphylococcus aureus. [22] Dodecahydrophenanthrene, 4-methylchrysazin and 4-hydroxy-7-methylindan-1-one These composites from the cells of Nostoc were reported. Dodecahydrophenanthrene demonstrates a selective strong antibacterial activity against Staphylococcus epidermidis equal to chloramphenicol. Middling antibacterial activity against S. epidermidis could be also found for 4-methylchrysazin and 4-hydroxy-7-methylindan-1-one and against Bacillus cereus for all 3 composites. [48] Antifungal compounds Nostofungicidine A recent lipopeptide, nostofungicidine, was derived from the methanolic extract of a field-grown terrestrial N. commune. [48] Nostofungicidine contains a novel b-AA, viz. 3-amino-6-hydroxystearic acid. Nostofungicidine exhibited strong antifungal activity against Aspergillus candidus and cytotoxicity against NSF-60 cell. [48, 58] Amino-6-hydroxy stearic acid This novel antifungal comprising cyclic peptide was derived from a terrestrial blue-green alga Nostoc commune. [22] Microviridins Microviridins, cyclic peptides with the particular structural characteristic of a tricyclic ring system, are the largest known cyanobacterial oligopeptides. [59] Nostopeptolides The derivation and total structure determinations of nostopeptolides A1, A2 and A3 were described by. [48] These cyclic depsipeptides, which are free of cytotoxic, antifungal and inhibition of peptidase activity, are characteristic components of the cryptophycin-producing Nostoc sp. None of the nostopeptolides showed notable cytotoxicity against KB and LoVo, [48] antifungal activity against Candida albicans, antibacterial activity against Pseudomonas aeruginosa, Mycobacterium tuberculosis, or interdiction of peptidase activity against trypsin, chymotrypsin, papain, thrombin, plasmin and against leucocyte elastase.
Nostocyclopeptides
Cyclic heptapeptides, viz. nostocyclopeptides A1, A2 and A3, owning an inimitable imino linkage in the macrocyclic ring, are characteristic components of the cryptophycin-producing cyanobacterium Nostoc sp. [48] Studies were accomplished on the biosynthesis and on the biological function of these cyclic peptides. The Nostocyclopeptides showed weak cytotoxicity against human nasopharyngeal carcinoma and human colorectal adenocarcinoma cell lines and were freed of antifungal activity (Candida albicans) and antibacterial activity (Pseudomonas aeruginosa, Mycobacterium tuberculosis). None of the composites showed notable inhibition of peptidase function against trypsin, thrombin and plasmin or opposed to chymotrypsin, elastase and papain. [48, 60] 
Antiprotozoal compound
Nostocarboline, an alkaloid derived from Nostoc sp. 78-12 A, was found to be active opposed Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani and Plasmodium falciparum with IC50 values ranging from 0.5 to 0.194 mM. [22] Algicidal compounds Cyanobacterins LU-1 and LU-2 These composites were reported from Nostoc linckia that are structurally different from cyanobacterin but specifically interdict transport of electron in photosystem II. It was found that LU-1 interdicts cyanobacteria as well as algae (but not photosynthetic microbes), while LU-2 is effective only for cyanobacteria. [61] Nostocine A A number of other metabolites such as Nostocyclamide, Nostocine A, Nostocarboline, etc., have been described from different species of Nostoc that are related with algaecidal function. [62] For example, a freshwater N.
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spongiaeforme constructed and excreted a novel violet pigment, Nostocine A, which had a broad spectrum of growthinhibiting function. [48] Nostocine A also interdicted the growth of some typical strains of microorganisms, algae, cultured plants and established animal cell lines. [48] To microalgae, Nostocine A showed a growth-inhibiting activity analogues to paraquat, and the function tended to be stronger to green algae than to cyanobacteria. Nostocine A also showed strong inhibitory function to root elongation of barnyard grass, strong counter-feeding activity to cotton ball worm and acute toxicity to mice resulting in its classification as a dangerous poison. The results suggest that Nostocine A may operate as a toxin or an allelochemical to breeding organisms in nature and that its unfavourable effects on various organisms may be related to its function in generating toxic reactive oxygen species, which occurs in the cells of target organisms. [48] Nostocarboline Newly, a composite Nostocarboline, an acetyl-and butyrylcholinesterase, and trypsin inhibitor from Nostoc 78-12A has been derived that show strong algicidal function opposed to both eukaryotic and prokaryotic phototrophs. [36] Nostocyclyne A A recent acetylene-containing acetylenic (1,4)-cyclophane, Nostocyclyne A, owning antimicrobial function, is the main active metabolite of the natural bloom of the Nostoc sp. Nostocyclyne A shows a feeble interdiction of photosynthesis of green algae. [48, 63, 64] Nostopeptins Nostopeptins A and B were derived from the cultured freshwater N. minutum. These cyclic depsipeptides comprising 3-amino-6-hydroxy-2-piperidone interdicted elastase and chymotrypsin. Nostopeptins A and B interdicted elastase and chymotrypsin, while neither composite interdicted papain, trypsin, thrombin or plasmin, even at 100 lg/ml. [65] Nostocyclamide A new anticyanobacterial and antialgal bioactive compound, Nostocyclamide, has been derived as a major component from the Nostoc sp. [48] Inhibitory activity was quantitatively determined opposed to the diatom Navicula minima; it was also toxic against Brachionus calyciflorus. A cyclic peptide Nostocyclamide M, containing thiazole and oxazole moieties, was derived from a freshwater Nostoc sp. Nostocyclamide M showed grazer toxicity and allelopathy opposed related cyanobacteria. [48, 66] 
Biomedical compounds
It has also been found that the Nostocarboline derived from the freshwater cyanobacterium Nostoc 78-12A is a strong cholinesterase inhibitor, which is an enzyme targeted in the treatment of Alzheimer's disease. Moreover, antimalarial and antileishmaniasis activities of these compound have been detected. [36] Rezanka et al. [11] have observed certain dioic acid in N. Linkia. Aliphatic dicarboxylic acids surprisingly afforded strong cytotoxicity and antineoplastic activity [48] and could distribute as lipidomic markers for identification of certain human and animal diseases. These acids are of main attention for medical specialists and biochemists. [48] 
Allelochemicals compounds
The extracts from the cyanobacterium Nostoc muscorum Agardh inhibited the in vitro growth of the fungal plant pathogens such as Sclerotinia sclerotiorum (cottony rot of vegetables and flowers) and Rhizoctonia solani (root and stem rots). [48, 67, 68] Photoprotective/UV-screening compounds Scytonemin Two mycosporine-like amino acids such as shinorine and scytonemin have been derived from some Nostoc species. Fleming and Castenholz [69] have lately noticed the effects of nitrogen source on the synthesis of scytonemin, in the cyanobacterium Nostoc punctiforme PCC 73102, and concluded that there was induction in the production of scytonemin when nitrogen content was discharged. [70, 71] Toxins and other pharmacologically active compounds
Nostoc species produce a large number of composites with varying bioactivities. These compounds include potent toxins, which are health risk for humans and animals. Nostoc toxins can be grouped into hepatoxins, neurotoxins and dermatotoxins on the basis of their mode of activity. The most well-characterized toxins produced by Nostoc species are the hepatotoxic cyclic peptides, microcystins and nodularins. [12, 48, 72] 
Microcystin (MC)
Several species of Nostoc are identified to produce hepatotoxic MC that are cyclic heptapeptides comprising of seven amino acids, including several D-amino acids and two unusual amino acids such as N-methyldehydroalanine (Mdha) and hydrophobic b-amino acid, 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid (Adda). It is the most detrimental freshwater bloom-forming cyanobacterium. [36, 48] Anatoxin A Anatoxin A, the neuromuscular blocking agent, was first derived from the freshwater cyanobacterium Anabaena flosaquae. [48, 73, 74] Later, it has been derived from other cyanobacterial species including N. muscorum. Its pharmacological properties have been inquired into and compared with that of artificial anatoxin A which was derived from lcocaine. Anatoxin A is a strong depolarizing neuromuscular blocking agent owning both muscarinic and nicotinic function. For example, nicotinic action of anatoxin A on guinea pig ileum antagonized by thymopentin and because of relatively low affinity of Anatoxin A for the muscarinic acetylcholine receptors of rat brain, it inhibited 3-[3H] quinuclidinyl benzilate binding. However, in contrast to classical muscarinic agonists, anatoxin A displays little regional selectivity in its binding, and its receptor affinity is unaltered by alkylation of the neural membranes with Nethylmaleimide. Moreover, it acts as a strong agonist of the secretory response of chromaffin cells. [22, 48] Nostophycin A recent cyclic peptide, nostophycin, possessing a weekly cytotoxic activity, was derived together with microcystins from the toxic Nostoc sp. [48] Nostophycin is composed of six amino acids (AA), viz. D-glutamine, glycine, L-phenylalanine, D-allo-isoleucine, 2 mol of L-proline and a novel b-AA, (2S,3R,5R)-3-amino-2,5-dihydroxy-8-phenyloctanoic acid. These results suggest that nostophycins are biosynthetically related to the microcystins, because they have a b-AA and two D-AA in common. [48, 75] 
Conclusion
The relative overlook in the past of cyanobacteria compared with other microbial sources of natural products, and the microbial variety of cyanobacteria, as well as the massive chemical and biologically active varieties of their products, suggest them as an attractive source of novel drugs for use in diverse therapeutic areas and should imply opportunity for a most notable progress in the generation of novel bioactive substances. Furthermore, Nostoc species also have the privilege over many other organisms as they can be cultured, thus providing an alternative to chemical synthesis for the production of their bioactive compounds.
In our review paper, chemically different and interesting compounds have been reviewed from Nostoc species. These data promise that further chemical and biological investigations may provide interesting finding. Nostoc species are a diverse and ancient group of photosynthetic prokaryotic organisms that can inhabit a wide range of environments including extreme conditions such as hot springs, desert soils and the Antarctic. They are abundant producers of natural products well recognized for their bioactivity and utility in drug discovery and biotechnology applications. Novel intracellular and extracellular compounds from various cultured and diverse biological activities and wide range of chemical classes have considerable potential for development of pharmaceutical and other biomedical applications. However, Nostoc species still viewed as unexplored source of potential drugs. Thus, we provided the comprehensive overview of metabolites and novel bioactive natural products produced by cyanobacteria of the genus Nostoc, which present biological activity and can be used for the treatment of various human and animal disorders. [48] Totally, the presented review proves that Nostoc species are a promising source to yield chemical and pharmaceutical interesting compounds.
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